Clinical pharmacokinetic–pharmacodynamic analyses: a critical element for developing antibacterial agents

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current opinion in pharmacology (Print)

• Publication date

  2017-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.coph.2017.09.010PMID 29154210
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo infection models in the pre‐clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents

  2017cited by this paper
• Pre‐clinical in vitro infection models

  2017cited by this paper
• Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance

  2017cited by this paper
• White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs

  2017cited by this paper
• Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products

  2016cited by this paper
• Evaluation of Exposure-Response Relationships Using Clinical Data: Basic Concepts and Applications

  2016cited by this paper
• Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia

  2011cited by this paper
• Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!

  2010cited by this paper
• Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.

  2008cited by this paper
• Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

  2007cited by this paper
• Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.

  2004cited by this paper
• Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.

  1999cited by this paper

• Optimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools

  2022cites this paper
• Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients

  2021cites this paper
• HPLC-MS/MS based comparative pharmacokinetics of 12 bioactive components in normal and osteoporosis rats after oral administration of You-Gui-Wan.

  2021cites this paper
• Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update

  2021cites this paper
• Combatting The Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.

  2020cites this paper
• Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model

  2020cites this paper
• Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents

  2019cites this paper
• The Role of Pharmacometrics in the Development of Antimicrobial Agents

  2018cites this paper
• Use of Monte Carlo simulation and considerations for PK‐PD targets to support antibacterial dose selection

  2017cites this paper
• Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogens.

  2017cites this paper